Skip to main content

Table 3 Cost inputs

From: Cost-effectiveness analysis of Tocilizumab compared to Adalimumab in the treatment of severe active rheumatoid arthritis in Iran

Cost Item

Description

Unit cost $

Total cost ($ 6 months)

Distribution

Treatment-related costs

-

TCZ

162 mg every other week

42.3

544.45

-

ADA

40 mg every other week

34.5

500.4

-

ETC

50 mg SC Once weekly

25.1

648.8

-

RTX

1000 mg IV, repeat after 2 weeks

128.3

574.3

-

Palliative care

weighted mean costs of cDMARDs, prednisolone, and celecoxib

NA

48.44

-

Diagnostic examination

 

Laboratory tests:

LFT and CBC

Every 2 months

8.46

25.39

-

Bone densitometry

Annually

17.17

8.58

-

Chest X-ray

Annually

5.72

2.86

-

Radiography

Annually

3.43

1.71

-

Tuberculin test

Annually

0.16

 

-

Other medical Cost

 

Hospitalization (per day) (SD)

Based on the HAQ score

31.82 (6.9)

Based on HAQ score

Gamma

Intra-articular corticosteroid

30% of patients on Palliative care

11.73

11.73

-

Mab Infusion

Based on treatment

8.01

Based on treatment

-

Psychotherapist

30% of patients on Palliative care every 3 months

8.15

16.3

-

  1. Abbreviations: ADA, Adalimumab; cDMARDs, conventional Disease-Modifying Antirheumatic Drugs; CBC, Complete Blood Count; ERT, Etanerecpt; HAQ, Health Assessment Questionnaire; IV, Intra Venous; LFT, Liver Function Tests; RTX, Rituximab; TCZ, Tocilizumab